Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (231-240 of 250) with videos related to

Pageof 25
Sort By:
Blood Cancer Journal|May 22, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trialNoemi Puig, Miguel T Hernández, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
American Journal of Human Genetics|December 6, 2024
Prequalification of genome-based newborn screening for severe childhood genetic diseases through federated training based on purifying hyperselectionStephen F Kingsmore, Meredith Wright, Laurie D Smith, et al.
Haematologica|July 11, 2024
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trialNoemí Puig, Cristina Agulló, Teresa Contreras, et al.
Blood|June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell developmentDaniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Annals of Hematology|October 22, 2024
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual diseaseSunil Lakhwani, María Victoria Mateos, Joaquín Martínez-López, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
The New England Journal of Medicine|June 5, 2023
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús San-Miguel, Binod Dhakal, Kwee Yong, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 25

Showing results (231-240 of 250) with videos related to

Sort By:
Pageof 25
Blood Cancer Journal|May 22, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trialNoemi Puig, Miguel T Hernández, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
American Journal of Human Genetics|December 6, 2024
Prequalification of genome-based newborn screening for severe childhood genetic diseases through federated training based on purifying hyperselectionStephen F Kingsmore, Meredith Wright, Laurie D Smith, et al.
Haematologica|July 11, 2024
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trialNoemí Puig, Cristina Agulló, Teresa Contreras, et al.
Blood|June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell developmentDaniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Annals of Hematology|October 22, 2024
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual diseaseSunil Lakhwani, María Victoria Mateos, Joaquín Martínez-López, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
The New England Journal of Medicine|June 5, 2023
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús San-Miguel, Binod Dhakal, Kwee Yong, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 25